TY - JOUR
T1 - The gold industry standard for risk and cost of drug and vaccine development revisited
AU - Pronker, E.S.
AU - Weenen, T.C.
AU - Commandeur, H.R.
AU - Osterhaus, A.D.M.E.
AU - Claassen, E.
PY - 2011
Y1 - 2011
N2 - Gold dimensions of pharmaceutical drug development indicate that it takes on average 11.9 years, with an investment around US$ 0.8 Billion, to launch one product on the market. Furthermore, approximately 22% of the drug candidates successfully complete clinical testing. These universally acknowledged proportions largely originate from one single, much cited publication; Dimasi et al. [5]. However an additional six articles describing new chemical entities (NCE) development were identified, which contain little, if any, information on vaccines. Published cumulative success rates range from 7% to 78% and investments calculations span US$ 0.8 to 1.7 Billion. Obviously this disserves further clarification? © 2011 Elsevier Ltd.
AB - Gold dimensions of pharmaceutical drug development indicate that it takes on average 11.9 years, with an investment around US$ 0.8 Billion, to launch one product on the market. Furthermore, approximately 22% of the drug candidates successfully complete clinical testing. These universally acknowledged proportions largely originate from one single, much cited publication; Dimasi et al. [5]. However an additional six articles describing new chemical entities (NCE) development were identified, which contain little, if any, information on vaccines. Published cumulative success rates range from 7% to 78% and investments calculations span US$ 0.8 to 1.7 Billion. Obviously this disserves further clarification? © 2011 Elsevier Ltd.
UR - https://www.scopus.com/pages/publications/79960719070
UR - https://www.scopus.com/inward/citedby.url?scp=79960719070&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2011.06.051
DO - 10.1016/j.vaccine.2011.06.051
M3 - Article
SN - 0264-410X
SP - 5846
EP - 5849
JO - Vaccine
JF - Vaccine
ER -
